Izotropic Corporation (IZOZF)
USD 0.03
(-10.45%)
USD 0.03
(-10.45%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -1.56 Million CAD | 72.42% |
| 2023 | -5.66 Million CAD | 14.93% |
| 2022 | -6.65 Million CAD | -33.73% |
| 2021 | -4.97 Million CAD | -330.52% |
| 2020 | -1.15 Million CAD | -190.02% |
| 2019 | -398.53 Thousand CAD | 45.42% |
| 2018 | -730.12 Thousand CAD | -642.61% |
| 2017 | -98.31 Thousand CAD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | -297.53 Thousand CAD | 62.46% |
| 2024 FY | -1.56 Million CAD | 72.42% |
| 2024 Q4 | 166.00 CAD | 100.06% |
| 2024 Q1 | -471.34 Thousand CAD | 68.7% |
| 2024 Q2 | -792.63 Thousand CAD | -68.17% |
| 2023 Q3 | -1.91 Million CAD | -38.39% |
| 2023 Q4 | -1.5 Million CAD | 21.45% |
| 2023 FY | -5.66 Million CAD | 14.93% |
| 2023 Q1 | -1.02 Million CAD | 37.51% |
| 2023 Q2 | -1.38 Million CAD | -35.0% |
| 2022 Q2 | -2.55 Million CAD | -108.74% |
| 2022 Q1 | -1.22 Million CAD | 35.73% |
| 2022 FY | -6.65 Million CAD | -33.73% |
| 2022 Q4 | -1.64 Million CAD | -32.0% |
| 2022 Q3 | -1.24 Million CAD | 51.33% |
| 2021 Q3 | -2.37 Million CAD | -538.67% |
| 2021 Q2 | -371.31 Thousand CAD | 17.27% |
| 2021 FY | -4.97 Million CAD | -330.52% |
| 2021 Q1 | -448.81 Thousand CAD | 25.83% |
| 2021 Q4 | -1.9 Million CAD | 19.66% |
| 2020 FY | -1.15 Million CAD | -190.02% |
| 2020 Q4 | -605.14 Thousand CAD | -143.13% |
| 2020 Q3 | -248.89 Thousand CAD | -60.18% |
| 2020 Q1 | -146.42 Thousand CAD | -5.64% |
| 2020 Q2 | -155.38 Thousand CAD | -6.12% |
| 2019 Q1 | -87.91 Thousand CAD | 43.32% |
| 2019 Q2 | -94.39 Thousand CAD | -7.37% |
| 2019 Q4 | -138.6 Thousand CAD | -78.55% |
| 2019 FY | -398.53 Thousand CAD | 45.42% |
| 2019 Q3 | -77.62 Thousand CAD | 17.76% |
| 2018 Q1 | -78.61 Thousand CAD | -125920.68% |
| 2018 Q2 | -427.41 Thousand CAD | -443.66% |
| 2018 Q3 | -68.98 Thousand CAD | 83.86% |
| 2018 Q4 | -155.11 Thousand CAD | -124.84% |
| 2018 FY | -730.12 Thousand CAD | -642.61% |
| 2017 Q1 | -14.83 CAD | 0.0% |
| 2017 Q4 | -62.39 CAD | -310.16% |
| 2017 FY | -98.31 Thousand CAD | 0.0% |
| 2017 Q2 | -22.10 CAD | -49.03% |
| 2017 Q3 | -15.21 CAD | 31.19% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| American Bio Medica Corporation | -1.41 Million USD | -10.734% |
| Arrayit Corporation | -3.31 Million USD | 52.909% |
| Atlantic International Corp. | -5.62 Million USD | 72.255% |
| Biocept, Inc. | -32.08 Million USD | 95.134% |
| Bioqual, Inc. | 483.48 Thousand USD | 422.941% |
| CardioGenics Holdings Inc | -1.91 Million USD | 18.523% |
| DermTech, Inc. | -100.88 Million USD | 98.452% |
| Global WholeHealth Partners Corporation | - USD | Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.02 Billion USD | 100.077% |
| HTG Molecular Diagnostics, Inc. | -21.59 Million USD | 92.77% |
| iMD Companies, Inc. | -200.63 Thousand USD | -678.203% |
| IDenta Corp. | 14.64 Thousand USD | 10762.087% |
| Interpace Biosciences, Inc. | 802 Thousand USD | 294.683% |
| Integrative Health Technologies, Inc. | 38.68 Thousand USD | 4135.659% |
| InVitro International | 1553.00 USD | 100638.055% |
| Lumos Diagnostics Holdings Limited | -8.59 Million USD | 81.828% |
| Many Bright Ideas Technologies Inc. | -58.11 Thousand USD | -2586.805% |
| Medical Imaging Corp. | -3.02 Million USD | 48.351% |
| NovelStem International Corp. | -4.18 Million USD | 62.712% |
| Optigenex Inc. | -2.89 Million USD | 46.119% |
| PharmChem, Inc. | 845.1 Thousand USD | 284.754% |
| Proteome Sciences plc | -2.44 Million USD | 36.089% |
| Response Genetics, Inc | -20.18 Million USD | 92.264% |
| Rennova Health, Inc. | -3.29 Million USD | 52.586% |
| RushNet, Inc. | -607.02 Thousand USD | -157.213% |
| ScreenPro Security Inc. | -2.24 Million USD | 30.568% |
| Stella Diagnostics Inc. | -5.7 Million USD | 72.643% |
| StageZero Life Sciences Ltd. | -11.41 Million USD | 86.322% |
| Todos Medical Ltd. | -24.99 Million USD | 93.753% |